Insight

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza/X

Dec 5, 2024, 07:25

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on X:

“Happy to share our last paper on the role of germline BRCA mutation in PARP inhibitors-related hematologic adverse events.

No differences between carriers vs. non-carriers.

Thanks to all the coauthors, Eleonora Nicolò, Dario Trapani, Luca Boscolo Bielo, Lorenzo Guidi, G Curigliano.”

Title: Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study

Authors: Carmine Valenza, Eleonora Nicolò, Marta Mongillo, Dario Trapani, Jalissa Katrini, Laura Boldrini, Luca Boscolo Bielo, Grazia Castellano, Lorenzo Guidi, Gloria Pellizzari, Jacopo Villa, Silvia Derio, Mariateresa Lapresa, Federica Gigli, Gabriella Parma, Emanuela Omodeo Salè, Enrico Derenzini, Giuseppe Curigliano and Nicoletta Colombo

Carmine Valenza

More posts featuring Carmine Valenza.

BRCA mutation cancer Carmine Valenza Dario Trapani Eleonora Nicolò Emanuela Omodeo Salè Enrico Derenzini germline Giuseppe Curigliano Gloria Pellizzari Grazia Castellano hematologic adverse events IEO Jacopo Villa Jalissa Katrini Laura Boldrini Lorenzo Guidi Luca Boscolo Bielo Mariateresa Lapresa Marta Mongillo Nicoletta Colombo OncoDaily Oncology PARP inhibitors Silvia Derio

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial